Citadel Advisors
LTRN icon

Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
+47,895
New +$140K ﹤0.01% 12071
2026
Q1 		– Sell
-32,895
Closed -$99.7K – 13688
2025
Q4 		$99.7K Buy
+32,895
New +$122K ﹤0.01% 11647
2025
Q1 		– Sell
-37,587
Closed -$156K – 15131
2024
Q4 		$120K Buy
37,587
+35,434
+1,646% +$121K ﹤0.01% 11189
2024
Q3 		$7.9K Buy
+2,153
New +$8.87K ﹤0.01% 13334
2024
Q1 		– Sell
-24,858
Closed -$133K – 15108
2023
Q4 		$106K Sell
24,858
-5,774
-19% -$20.4K ﹤0.01% 10855
2023
Q3 		$104K Buy
30,632
+5,895
+24% +$26.8K ﹤0.01% 10841
2023
Q2 		$140K Buy
24,737
+13,761
+125% +$71.1K ﹤0.01% 10433
2023
Q1 		$53K Sell
10,976
-8,345
-43% -$43.8K ﹤0.01% 12080
2022
Q4 		$117K Buy
19,321
+6,568
+52% +$32.9K ﹤0.01% 11004
2022
Q3 		$61K Buy
+12,753
New +$68.6K ﹤0.01% 11489
2022
Q1 		– Sell
-11,095
Closed -$89K – 14172
2021
Q4 		$89K Buy
+11,095
New +$101K ﹤0.01% 12829
2021
Q2 		– Sell
-11,192
Closed -$203K – 14085
2021
Q1 		$203K Buy
+11,192
New +$196K ﹤0.01% 11667

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q2 2026 in Review

Citadel Advisors opened a new position in Lantern Pharma (LTRN) in Q2 2026: 47,895 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #12071 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LTRN as recently as Q4 2025.

Citadel Advisors first reported a position in LTRN in Q1 2021 and has held it in 12 quarters since. The position peaked at $203K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Citadel Advisors held 47,895 shares of Lantern Pharma worth $200K as of Q2 2026.
  • Lantern Pharma was a new Citadel Advisors position in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12071 holding.
  • Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.